Patent · US Active

Inhibitors of the menin-MLL interaction

US11919901B2 · kind B2 · utility

0Cited by

16References

28Claims

0Family size

Assignees

Syndax Pharmaceuticals, Inc. · US
Vitae Pharmaceuticals, LLC · US

Inventors

Gerard McGeehan · Chester Springs, US
William Henry Miller · Collegeville, US
Nicholas Paul Camp · Chertsey, GB
Salvacion Cacatian · Conshohocken, US
Santosh S. Kulkarni · Kanchinakote, IN
Swapan Kumar Samanta · Kanchinakote, IN
Virsinha Venkat Reddy · Kanchinakote, IN

Key dates

Filing date	May 13, 2022
Grant date	Mar 5, 2024
Priority date	—
Expiry date	May 13, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.